Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy

Cancer Research

Volumn 67, Issue 1, 2007, Pages 300-308

  Thanarajasingam, Uma ^a   Sanz, Laura ^a   Diaz, Rosa ^a   Qiao, Jian ^a   Sanchez Perez, Luis ^a   Kottke, Tim ^a   Thompson, Jill ^a   Chester, John ^b   Vile, Richard G ^a  

^a MAYO CLINIC   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

L SELECTIN; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL THERAPY; CONTROLLED STUDY; CYTOTOXICITY; IN VITRO STUDY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; DOWN-REGULATION; FEMALE; IMMUNOTHERAPY, ADOPTIVE; L-SELECTIN; MALE; MELANOMA, EXPERIMENTAL; MICE; T-LYMPHOCYTES; TRANSFECTION;

EID: 33846414710     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1017     Document Type: Article

References (39)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
2. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14639-45.
3. Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003;3:431-7.
4. + T cells. J Clin Invest 2005;115:1616-26.
5. + T cells. J Exp Med 2005;202:907-12.
6. + T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol 2004;173:7209-16.
7. Wang LX, Shu S, Plautz GE. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res 2005;65:9547-54.
8. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75.
9. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-620.
10. Schau TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994;6:865-73.
11. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001;2:123-8.
12. Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286:2098-102.
13. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 1998;95:258-63.
14. Saeki H, Moore AM, Brown MJ, Hwang ST. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 1999;162:2472-5.
15. Sanchez-Sanchez N, Riol-Blanco L, de la Rosa G, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 2004;104:619-25.
16. + T lymphocytes from apoptosis. Clin Cancer Res 2005;11:7901-10.
17. Willimann K, Legler DF, Loetscher M, et al. The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7. Eur J Immunol 1998;28:2025-34.
18. Warnock RA, Campbell JJ, Dorf ME, Matsuzawa A, McEvoy LM, Butcher EC. The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. J Exp Med 2000;191:77-88.
19. Hedrick JA, Zlotnik A. Identification and characterization of a novel β chemokine containing six conserved cysteines. J Immunol 1997;159:1589-93.
20. Hromas R, Kim CH, Klemsz M, et al. Isolation and characterization of Exodus-2, a novel C-C chemokine with a unique 37-amino acid carboxyl-terminal extension. J Immunol 1997;159:2554-8.
21. Tanabe S, Lu Z, Luo Y, et al. Identification of a new mouse β-chemokine, thymus-derived chemotactic agent 4, with activity on T lymphocytes and mesangial cells. J Immunol 1997;159:5671-9.
22. Stein JV, Rot A, Luo Y, et al. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J Exp Med 2000;191:61-76.
23. Nakano H, Tamura T, Yoshimoto T, et al. Genetic defect in T lymphocyte-specific homing into peripheral lymph nodes. Eur J Immunol 1997;27:215-21.
24. Nakano H, Mori S, Yonekawa H, Nariuchi H, Matsuzawa A, Kakiuchi T. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood 1998;91:2886-95.
25. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res 2001;61:2062-70.
26. Yang SC, Hillinger S, Riedl K, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004;10:2891-901.
27. Vieari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000;165:1992-2000.
28. Hogquist KA Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17-27.
29. Cole C, Qiao J, Kottke T, et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005;11:1073-81.
30. Kottke T, Qiao J, Diaz RM, et al. The perforin-dependent immunological synapse allows T cell activation-dependent tumor targeting my MLV vector particles. Gene Ther 2006;13:1166-77.
31. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998;4:581-7.
32. Linardakis E, Bateman A, Phan V, et al. Enhancing the efficacy of a weak allogeneic melanoma vaccina by viral fiisogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002;62:5495-504.
33. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988;167:400-6.
34. Weninger W, von Andrian UH. Chemokine regulation of naive T cell traffic in health and disease. Semin Immunol 2003;15:257-70.
35. + T cells. J Immunol 2003;170:5018-26.
36. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002;2:85-95.
37. + T cell adoptive immunotherapy. Immunity 2000;13:265-76.
38. Matsui K, O'Mara LA, Allen PM. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. Int Immunol 2003;15:797~805.
39. Robbins PF, Dudley ME, Wunderlich J, et al. Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-30.